Vivus Plans Evamist NDA In Q4 2006, But Obesity Combo Qnexa Is Top Priority
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
While Vivus is getting ready to submit its NDA for Evamist early in the fourth quarter of 2006, the company is calling its obesity drug Qnexa a potential blockbuster and earmarking it as its top priority.